The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Studying the process of brain formation illuminates just how much of development is a series of tiny miracles. Only a few ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

In the past decade, there has been significant interest in studying the expression of our genetic code down to the level of ...

Single-cell proteomics with RNA sequencing uncover hidden gene expression dynamics in stem cell differentiation.

By late 2021, mRNA vaccines had saved an estimated 7.7m lives globally, including most of the 3m Americans whom the Commonwealth Fund, an American health-care charity, estimates were saved by vaccines ...

An announcement from Ionis Pharmaceuticals ( (IONS) ) is now available. On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved DAWNZERA™ (donidalorsen) for preventing hereditary ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

Senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist, said the results reveal a potential new treatment path — an alternative to surgery, radiation, and chemotherapy — with broad ...

In the past decade there has been significant interest in studying the expression of our genetic code down to the level of ...